Biotech startup Laekna snags $61m and 20 more deal updates worth $298m

Laekna Therapeutics, a Chinese biotech startup that develops innovative therapeutics to treat cancer and liver diseases, announced on Wednesday the completion of a Series D funding round at $61 million to speed up the clinical trials of its drug pipeline.

The round was led by CMG-SDIC Capital, a private equity (PE) firm co-launched by China’s SDIC Fund Management and China Merchants Capital. Existing shareholder Yanchuang Capital participated in the deal, alongside Wanhui Capital and Infinity Capital.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter